Plasma DPP4 activity was measured by detecting p-nitroaniline (pNa) resolved from GP-pNa (Bachem L1880, Swiss), a DPP4 substrate43 (link). In brief, 5 µl blood samples were added to 150 µl of 50 mM tris-HCL containing 1 mM GP-pNa, and then the spectrophotometer at 405 nm was read immediately and 1 hour later. The activity is expressed as U/L, indicating that 1 mmol pNa is produced per minute at 37 °C. Biochemical measurements, including those of plasma glucose (GLUC3 Assay, Roche, Germany), cholesterol (CREP2/CHOL2/TRIGL/LDL_C/HDLC3 Assay, Roche, Germany), the MB isoenzyme of creatine kinase (CK-MB) (Elecsys CK-MB Assay, Roche, Germany), cardiac troponin T (cTNT) (Elecsys Troponin T hs Assay, Roche, Germany), NT-proBNP (Elecsys proBNP II Assay, Roche, Germany) and creatinine (CREP2 Assay, Roche, Germany) were obtained using standard clinical analytical methods (Cobas Roche, Germany). For plasma glucose, creatinine and lipid profile measurements we used the Cobas c701 platform (Roche, Swiss). For myocardial injury markers (CK-MB, cTnT and NT-proBNP) measurements we used the Cobas e602 platform (Roche, Swiss). The normal range of the NT-proBNP test was <150 pg/mL.
Cobas e602 platform
Manufactured by Roche
Sourced in Switzerland, Japan
The Cobas e602 platform is a fully automated immunoassay analyzer developed by Roche. It is designed for the quantitative and qualitative determination of various analytes in biological samples. The Cobas e602 platform utilizes electrochemiluminescence technology to perform immunoassay tests, providing reliable and accurate results. Its core function is to serve as a high-throughput solution for clinical laboratories and diagnostic facilities.
Automatically generated - may contain errors
Lab products found in correlation
Elecsys troponin t hs assay, by Roche (1 mentions)
Elecsys probnp 2 assay, by Roche (1 mentions)
L1880, by Bachem (1 mentions)
Crep2 assay, by Roche (1 mentions)
Architect i2000sr platform, by Abbott (1 mentions)
Sars cov 2 igg assay, by Abbott (1 mentions)
Advia centaur xp platform, by Siemens (1 mentions)
Anti sars cov 2 assay, by Roche (1 mentions)
Cobas 8000 platform, by Roche (1 mentions)
Elecsys nt probnp 2, by Roche (1 mentions)
4 protocols using cobas e602 platform
1
Biochemical Measurement of Plasma Biomarkers
2
Evaluating SARS-CoV-2 Antibody Assays
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
We evaluated the performance of the following fully automated CLIA tests on high throughput random access analyzers widely available in medical laboratories: Roche Elecsys Anti-SARS-CoV-2 assay on the Cobas e602 platform (Roche Diagnostics, Rotkreuz, Switzerland), Abbott SARS-CoV-2 IgG assay on the Architect i2000SR platform (Abbott Laboratories Abbott Park, IL, USA), Siemens SARS-CoV-2 total (COV2T) and SARS-CoV-2 IgG (COV2G) on the Advia Centaur XP platform (Siemens, Munich, Germany). All samples were processed according to the manufacturers' procedures with the specified controls and calibrators by trained laboratory staff. Test characteristics given in the manufacturers' product information are summarized in Supplementary Table S1. Precision was evaluated by repeatedly measuring the positive controls of the respective assays (Supplementary Results).
3
Osteogenic Differentiation of aBMSCs on Scaffolds
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
aBMSCs on nHAC/PLA scaffolds were cultured for 21 days in basic medium or osteogenic induction medium at 1.5 × 104/cm2 cells per graft. The supernatants were collected at 3 time points: days 7, 14, and 21. The ALP activity in the medium was assayed using Roche Diagnostics ALP kits on the cobas e602 platform (Roche Diagnostics, Mannheim, Germany), and calcium content and phosphonium content were assayed using Roche Diagnostics Ca/P kits. OCN activity was assayed using N-MID osteocalcin kits, based on electrochemiluminescence immunoassay techniques. All data were measured and analyzed on the cobas 8000 platform (Roche Diagnostics).
4
Plasma BNP and NT-proBNP Measurement
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Blood samples were obtained in the early morning ≤24 h after admission. These samples were transferred to chilled tubes containing 4.5 mg ethylenediaminetetraacetic acid, disodium salt and aprotinin (500 U/mL) and were centrifuged at 1,000×g for 15 min at 4℃. The clarified plasma samples were frozen, stored at −70℃, and thawed immediately before the assay was performed. BNP concentration was measured using a commercially available radioimmunoassay specific for human BNP (Shiono RIA BNP assay kit, Shionogi, Tokyo, Japan).16 (link)
To perform an exact comparison between BNP and NT-proBNP, plasma samples that were obtained simultaneously, were used for NT-proBNP measurement. NT-proBNP was measured with an electrochemiluminescence immunoassay: the Elecsys NT-proBNP II on the cobas e602 platform (Roche Diagnostics, Tokyo, Japan).
Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease equation with the Japanese coefficient.17 (link)
CKD was defined as reduced eGFR (<60 mL/min/1.73 m2) according to the Kidney Disease Outcomes Quality Initiative (K/DOQI) clinical guidelines.18 (link),19 (link)
Anemia was defined as hemoglobin <13 g/dL in male subjects and <12 g/dL in female subjects according to the World Health Organization guidelines. CRAS was defined as anemia with CKD.
To perform an exact comparison between BNP and NT-proBNP, plasma samples that were obtained simultaneously, were used for NT-proBNP measurement. NT-proBNP was measured with an electrochemiluminescence immunoassay: the Elecsys NT-proBNP II on the cobas e602 platform (Roche Diagnostics, Tokyo, Japan).
Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease equation with the Japanese coefficient.17 (link)
CKD was defined as reduced eGFR (<60 mL/min/1.73 m2) according to the Kidney Disease Outcomes Quality Initiative (K/DOQI) clinical guidelines.18 (link),19 (link)
Anemia was defined as hemoglobin <13 g/dL in male subjects and <12 g/dL in female subjects according to the World Health Organization guidelines. CRAS was defined as anemia with CKD.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!